Page 101 - Read Online

Ma et al. J Cancer Metastasis Treat 2022;8:25 https://dx.doi.org/10.20517/2394-4722.2022.17 Page 19 of 20

the DSHNHL2006-1B/ACT-2 trial. Leukemia 2021;35:143-55. DOI PubMed
65. Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in
angioimmunoblastic T-cell lymphoma. Blood Adv 2021;5:539-48. DOI PubMed PMC
66. Haverkos B, Zain J, Kamdar M, et al. A pilot study using nivolumab in combination with standard of care chemotherapy in newly
diagnosed peripheral T-Cell lymphomas. Blood 2021;138:2444. DOI
67. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression:
spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970-6. DOI PubMed
68. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine
receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol
2014;32:1157-63. DOI PubMed
69. O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of
the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 2015;33:2492-9. DOI PubMed PMC
70. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab
vedotin. Blood 2014;123:3095-100. DOI PubMed PMC
71. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory
peripheral T-cell lymphoma. Ann Oncol 2015;26:1766-71. DOI
72. Maruyama D, Nagai H, Maeda Y, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-
cell lymphoma. Cancer Sci 2017;108:2061-8. DOI PubMed PMC
73. Hong X, Song Y, Huang H, et al. Pralatrexate in chinese patients with relapsed or refractory peripheral T-Cell lymphoma: a single-
arm, multicenter study. Target Oncol 2019;14:149-58. DOI PubMed PMC
74. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy
for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-7. DOI PubMed PMC
75. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory
cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-91. DOI PubMed
76. Maruyama D, Tobinai K, Ogura M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a
phase I/II and pharmacokinetics study. Int J Hematol 2017;106:655-65. DOI PubMed
77. Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma
patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol 2016;27:508-13. DOI
78. Kim JH, Kim WS, Park C. Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T
cell lymphoma; potential implications for HDACi-mediated fatal complications. Antiviral Res 2021;189:105063. DOI PubMed
79. Sawas A, Ma H, Shustov A, et al. Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic
T-cell lymphoma. Leuk Lymphoma 2020;61:2003-7. DOI
80. Maruyama D, Tsukasaki K, Uchida T, et al. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell
lymphoma. Ann Hematol 2019;98:131-42. DOI PubMed PMC
81. Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator’s choice of chemotherapy regimen in
relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2019;104:993-1003. DOI PubMed PMC
82. Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-Cell
leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease,
nonrelapse mortality, and overall mortality. J Clin Oncol 2016;34:3426-33. DOI PubMed
83. Saillard C, Guermouche H, Derrieux C, et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell
lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. Hematol Oncol
2017;35:864-8. DOI PubMed
84. Cheminant M, Bruneau J, Kosmider O, et al. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br
J Haematol 2015;168:913-6. DOI PubMed
85. Lemonnier F, Dupuis J, Sujobert P, et al. Treatment with 5-azacytidine induces a sustained response in patients with
angioimmunoblastic T-cell lymphoma. Blood 2018;132:2305-9. DOI PubMed
86. Horwitz SM, Mehta-shah N, Pro B, et al. Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-Cell
lymphoma from the phase 2 primo trial: selection of regimen for the dose-expansion phase. Blood 2019;134:1567. DOI
87. Brammer JE, Zinzani PL, Zain J, et al. Duvelisib in patients with relapsed/refractory peripheral T-Cell lymphoma from the phase 2
Primo trial: results of an interim analysis. Blood 2021;138:2456-2456. DOI
88. Huen A, Haverkos BM, Zain J, et al. Phase I/Ib study of Tenalisib (RP6530), a Dual PI3K δ/γ inhibitor in patients with
relapsed/refractory T-Cell lymphoma. Cancers (Basel) 2020;12:2293. DOI PubMed PMC
89. Barta SK, Zain J, MacFarlane AW, et al. Phase II study of the PD-1 Inhibitor pembrolizumab for the treatment of relapsed or
refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2019;19:356-364.e3. DOI
90. Bennani NN, Pederson LD, Atherton P, et al. A phase II study of nivolumab in patients with relapsed or refractory peripheral T-Cell
lymphoma. Blood 2019;134:467-467. DOI
91. Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor
therapy. N Engl J Med 2018;378:1947-8. DOI PubMed
92. Rauch DA, Conlon KC, Janakiram M, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after